Skip to main content
. 2020 Nov 11;42(2):178–188. doi: 10.1093/eurheartj/ehaa898

Figure 5.

Figure 5

Plasma miR-132 levels in patients after CDR132L treatment. (A) Median with 25%/75% interquartile ranges of plasma miR-132 levels in patients over the study course (pre = immediately before, post = 1h after administration). (B) Individual median miR-132 levels in healthy subjects (n = 30; blood bank samples) and in patients (n = 25) at study end (Day 112). P-value: Mann–Whitney U test comparing to the placebo group.